YD Bio Ltd Stock: price and insider trades · United States
1 insider bought €111k of shares over the last 90 days, the latest by Shen Ethan PhD, filed 16 Sept 2026.
YD Bio Ltd: what insiders have been doing
This page follows insider dealings at YD Bio Ltd as filed with SEC (Form 4). Over the twelve months to 8 November 2026, 8 filings were filed, from 3 insiders.
The flow runs one way only: 1 insider bought (3 purchases totalling €111k) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €58k, bought by Shen Ethan PhD and made public on 8 September 2026 (0.017% of market cap). Those buying include 1 chief executive.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 8 filings, this issuer sits below that mark. Since 2026, the database holds 3 purchases and no sales by insiders of the company. On the fundamentals side, the SEC filing (20-F) for the period ending 31 December 2025 lists revenue at 596,817 USD and net income at -8.3 m USD.
The last purchase on record was published on 16 September 2026, which is 53 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +58.2%Entry US$0.39 · Close at T+30 US$0.62
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 3,135 sharesOrdinary SharesSEC:0001213900-26-107185:0
- 3,135 sharesOrdinary SharesSEC:0001213900-26-107184:0
- 12,700 shares@ US$3.8538.1% of flowOrdinary SharesSEC:0001213900-26-100506:0Canonical exit: 13 Dec 2026 (T+90)
- 3,100 shares@ US$3.939.5% of flowOrdinary SharesSEC:0001213900-26-098775:0Canonical exit: 8 Dec 2026 (T+90)
- 18,378 shares@ US$3.6752.4% of flowOrdinary SharesSEC:0001213900-26-098030:0Canonical exit: 3 Dec 2026 (T+90)
- 5,749 sharesOrdinary SharesSEC:0001213900-26-074187:0
- 2,081 sharesOrdinary SharesSEC:0001213900-26-039316:0
- 2,081 sharesOrdinary SharesSEC:0001213900-26-039317:0
8 of 8 declarations
About YD Bio Ltd
YD Bio Ltd is a company listed on the XNAS market, specializing in the biotechnology sector. It focuses on developing innovative solutions for disease treatment.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
